The deal was closed on January 1, 2010. It was agreed not to disclose details of the purchase price.
The site has a workforce of some 650 and produces active ingredients and intermediates for the pharmaceuticals industry.
The deal includes a long-term partnership with Lilly for the production of active ingredients and a multi-year supply agreement for active ingredients and intermediates for pharmaceuticals.
The site will be fully integrated into Evonik’s global production and marketing network.